Arsenic methylation and bladder cancer risk in Taiwan

Yen Ching Chen, Huey Jen Jenny Su, Yu Liang Leon Guo, Yu-Mei Hsueh, Thomas J. Smith, Louise M. Ryan, Meei Shyuan Lee, David C. Christiani

Research output: Contribution to journalArticle

196 Citations (Scopus)

Abstract

Objective: The mechanism of arsenic detoxification in humans remains unclear. Data are especially lacking for low-level arsenic exposure. We hypothesize that arsenic methylation ability, defined as the ratios of monomethylarsonic acid (MMA(V))/inorganic arsenic (primary arsenic methylation index, PMI) and dimethylarsinic acid (DMA(V))/MMA(V) (secondary arsenic methylation index, SMI), may modify the association between cumulative arsenic exposure (CAE, mg/L-year) and the risk of bladder cancer. In this study we investigated the relationship among arsenic methylation ability, CAE, and the risk of bladder cancer in a hospital-based case-control study in southwestern Taiwan. Methods: From January 1996 to December 1999 we identified 49 patients with newly diagnosed cases of bladder cancer at the National Cheng-Kung University (NCKU) Medical Center; controls consisted of 224 fracture and cataract patients selected from the same medical center. The levels of four urinary arsenic species: arsenite (As(III)), arsenate (As(V)), MMA(V), and DMA(V)) were determined in all subjects by using the high-performance liquid chromatography hydride-generation atomic absorption spectrometry (HPLC-HGAAS). CAE was estimated by using published data collected in a survey from 1974 to 1976. Results: Compared to a CAE ≦ 2 mg/L-year, CAE > 12 mg/L-year was associated with an increased risk of bladder cancer (multivariate odds ratio (OR) 4.23, 95% confidence interval (CI) 1.12-16.01), in the setting of a low SMI (≦4.8). Compared to women, smoking men (OR 6.23, 95% CI 1.88-20.62) and non-smoking men (OR 3.25, 95% CI 0.95-11.06) had higher risks of bladder cancer. Given the same level of PMI, smoking men (OR 9.80, 95% CI 2.40-40.10) and non-smoking men (OR 4.45, 95% CI 1.00-19.84) had a higher risk of bladder cancer when compared to women. With the same level of SMI, both smoking men (OR 6.28, 95% CI 1.76-22.39) and non-smoking men (OR 3.31, 95% CI 0.84-12.97) had a higher risk of bladder cancer when compared to women. Conclusions: Subjects with low SMI have a substantially increased risk of bladder cancer, especially when combined with high CAE levels.

Original languageEnglish
Pages (from-to)303-310
Number of pages8
JournalCancer Causes and Control
Volume14
Issue number4
DOIs
Publication statusPublished - May 2003

Fingerprint

Arsenic
Taiwan
Urinary Bladder Neoplasms
Methylation
Odds Ratio
Confidence Intervals
Aptitude
Smoking
Cacodylic Acid
Cataract
Case-Control Studies
Spectrum Analysis
High Pressure Liquid Chromatography

Keywords

  • Arsenic methylation ability
  • Bladder cancer
  • Cumulative arsenic exposure
  • Taiwan

ASJC Scopus subject areas

  • Oncology
  • Epidemiology
  • Cancer Research

Cite this

Chen, Y. C., Su, H. J. J., Guo, Y. L. L., Hsueh, Y-M., Smith, T. J., Ryan, L. M., ... Christiani, D. C. (2003). Arsenic methylation and bladder cancer risk in Taiwan. Cancer Causes and Control, 14(4), 303-310. https://doi.org/10.1023/A:1023905900171

Arsenic methylation and bladder cancer risk in Taiwan. / Chen, Yen Ching; Su, Huey Jen Jenny; Guo, Yu Liang Leon; Hsueh, Yu-Mei; Smith, Thomas J.; Ryan, Louise M.; Lee, Meei Shyuan; Christiani, David C.

In: Cancer Causes and Control, Vol. 14, No. 4, 05.2003, p. 303-310.

Research output: Contribution to journalArticle

Chen, YC, Su, HJJ, Guo, YLL, Hsueh, Y-M, Smith, TJ, Ryan, LM, Lee, MS & Christiani, DC 2003, 'Arsenic methylation and bladder cancer risk in Taiwan', Cancer Causes and Control, vol. 14, no. 4, pp. 303-310. https://doi.org/10.1023/A:1023905900171
Chen, Yen Ching ; Su, Huey Jen Jenny ; Guo, Yu Liang Leon ; Hsueh, Yu-Mei ; Smith, Thomas J. ; Ryan, Louise M. ; Lee, Meei Shyuan ; Christiani, David C. / Arsenic methylation and bladder cancer risk in Taiwan. In: Cancer Causes and Control. 2003 ; Vol. 14, No. 4. pp. 303-310.
@article{9d6b9492721742a09522a70dabf86f65,
title = "Arsenic methylation and bladder cancer risk in Taiwan",
abstract = "Objective: The mechanism of arsenic detoxification in humans remains unclear. Data are especially lacking for low-level arsenic exposure. We hypothesize that arsenic methylation ability, defined as the ratios of monomethylarsonic acid (MMA(V))/inorganic arsenic (primary arsenic methylation index, PMI) and dimethylarsinic acid (DMA(V))/MMA(V) (secondary arsenic methylation index, SMI), may modify the association between cumulative arsenic exposure (CAE, mg/L-year) and the risk of bladder cancer. In this study we investigated the relationship among arsenic methylation ability, CAE, and the risk of bladder cancer in a hospital-based case-control study in southwestern Taiwan. Methods: From January 1996 to December 1999 we identified 49 patients with newly diagnosed cases of bladder cancer at the National Cheng-Kung University (NCKU) Medical Center; controls consisted of 224 fracture and cataract patients selected from the same medical center. The levels of four urinary arsenic species: arsenite (As(III)), arsenate (As(V)), MMA(V), and DMA(V)) were determined in all subjects by using the high-performance liquid chromatography hydride-generation atomic absorption spectrometry (HPLC-HGAAS). CAE was estimated by using published data collected in a survey from 1974 to 1976. Results: Compared to a CAE ≦ 2 mg/L-year, CAE > 12 mg/L-year was associated with an increased risk of bladder cancer (multivariate odds ratio (OR) 4.23, 95{\%} confidence interval (CI) 1.12-16.01), in the setting of a low SMI (≦4.8). Compared to women, smoking men (OR 6.23, 95{\%} CI 1.88-20.62) and non-smoking men (OR 3.25, 95{\%} CI 0.95-11.06) had higher risks of bladder cancer. Given the same level of PMI, smoking men (OR 9.80, 95{\%} CI 2.40-40.10) and non-smoking men (OR 4.45, 95{\%} CI 1.00-19.84) had a higher risk of bladder cancer when compared to women. With the same level of SMI, both smoking men (OR 6.28, 95{\%} CI 1.76-22.39) and non-smoking men (OR 3.31, 95{\%} CI 0.84-12.97) had a higher risk of bladder cancer when compared to women. Conclusions: Subjects with low SMI have a substantially increased risk of bladder cancer, especially when combined with high CAE levels.",
keywords = "Arsenic methylation ability, Bladder cancer, Cumulative arsenic exposure, Taiwan",
author = "Chen, {Yen Ching} and Su, {Huey Jen Jenny} and Guo, {Yu Liang Leon} and Yu-Mei Hsueh and Smith, {Thomas J.} and Ryan, {Louise M.} and Lee, {Meei Shyuan} and Christiani, {David C.}",
year = "2003",
month = "5",
doi = "10.1023/A:1023905900171",
language = "English",
volume = "14",
pages = "303--310",
journal = "Cancer Causes and Control",
issn = "0957-5243",
publisher = "Springer Netherlands",
number = "4",

}

TY - JOUR

T1 - Arsenic methylation and bladder cancer risk in Taiwan

AU - Chen, Yen Ching

AU - Su, Huey Jen Jenny

AU - Guo, Yu Liang Leon

AU - Hsueh, Yu-Mei

AU - Smith, Thomas J.

AU - Ryan, Louise M.

AU - Lee, Meei Shyuan

AU - Christiani, David C.

PY - 2003/5

Y1 - 2003/5

N2 - Objective: The mechanism of arsenic detoxification in humans remains unclear. Data are especially lacking for low-level arsenic exposure. We hypothesize that arsenic methylation ability, defined as the ratios of monomethylarsonic acid (MMA(V))/inorganic arsenic (primary arsenic methylation index, PMI) and dimethylarsinic acid (DMA(V))/MMA(V) (secondary arsenic methylation index, SMI), may modify the association between cumulative arsenic exposure (CAE, mg/L-year) and the risk of bladder cancer. In this study we investigated the relationship among arsenic methylation ability, CAE, and the risk of bladder cancer in a hospital-based case-control study in southwestern Taiwan. Methods: From January 1996 to December 1999 we identified 49 patients with newly diagnosed cases of bladder cancer at the National Cheng-Kung University (NCKU) Medical Center; controls consisted of 224 fracture and cataract patients selected from the same medical center. The levels of four urinary arsenic species: arsenite (As(III)), arsenate (As(V)), MMA(V), and DMA(V)) were determined in all subjects by using the high-performance liquid chromatography hydride-generation atomic absorption spectrometry (HPLC-HGAAS). CAE was estimated by using published data collected in a survey from 1974 to 1976. Results: Compared to a CAE ≦ 2 mg/L-year, CAE > 12 mg/L-year was associated with an increased risk of bladder cancer (multivariate odds ratio (OR) 4.23, 95% confidence interval (CI) 1.12-16.01), in the setting of a low SMI (≦4.8). Compared to women, smoking men (OR 6.23, 95% CI 1.88-20.62) and non-smoking men (OR 3.25, 95% CI 0.95-11.06) had higher risks of bladder cancer. Given the same level of PMI, smoking men (OR 9.80, 95% CI 2.40-40.10) and non-smoking men (OR 4.45, 95% CI 1.00-19.84) had a higher risk of bladder cancer when compared to women. With the same level of SMI, both smoking men (OR 6.28, 95% CI 1.76-22.39) and non-smoking men (OR 3.31, 95% CI 0.84-12.97) had a higher risk of bladder cancer when compared to women. Conclusions: Subjects with low SMI have a substantially increased risk of bladder cancer, especially when combined with high CAE levels.

AB - Objective: The mechanism of arsenic detoxification in humans remains unclear. Data are especially lacking for low-level arsenic exposure. We hypothesize that arsenic methylation ability, defined as the ratios of monomethylarsonic acid (MMA(V))/inorganic arsenic (primary arsenic methylation index, PMI) and dimethylarsinic acid (DMA(V))/MMA(V) (secondary arsenic methylation index, SMI), may modify the association between cumulative arsenic exposure (CAE, mg/L-year) and the risk of bladder cancer. In this study we investigated the relationship among arsenic methylation ability, CAE, and the risk of bladder cancer in a hospital-based case-control study in southwestern Taiwan. Methods: From January 1996 to December 1999 we identified 49 patients with newly diagnosed cases of bladder cancer at the National Cheng-Kung University (NCKU) Medical Center; controls consisted of 224 fracture and cataract patients selected from the same medical center. The levels of four urinary arsenic species: arsenite (As(III)), arsenate (As(V)), MMA(V), and DMA(V)) were determined in all subjects by using the high-performance liquid chromatography hydride-generation atomic absorption spectrometry (HPLC-HGAAS). CAE was estimated by using published data collected in a survey from 1974 to 1976. Results: Compared to a CAE ≦ 2 mg/L-year, CAE > 12 mg/L-year was associated with an increased risk of bladder cancer (multivariate odds ratio (OR) 4.23, 95% confidence interval (CI) 1.12-16.01), in the setting of a low SMI (≦4.8). Compared to women, smoking men (OR 6.23, 95% CI 1.88-20.62) and non-smoking men (OR 3.25, 95% CI 0.95-11.06) had higher risks of bladder cancer. Given the same level of PMI, smoking men (OR 9.80, 95% CI 2.40-40.10) and non-smoking men (OR 4.45, 95% CI 1.00-19.84) had a higher risk of bladder cancer when compared to women. With the same level of SMI, both smoking men (OR 6.28, 95% CI 1.76-22.39) and non-smoking men (OR 3.31, 95% CI 0.84-12.97) had a higher risk of bladder cancer when compared to women. Conclusions: Subjects with low SMI have a substantially increased risk of bladder cancer, especially when combined with high CAE levels.

KW - Arsenic methylation ability

KW - Bladder cancer

KW - Cumulative arsenic exposure

KW - Taiwan

UR - http://www.scopus.com/inward/record.url?scp=0038715897&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0038715897&partnerID=8YFLogxK

U2 - 10.1023/A:1023905900171

DO - 10.1023/A:1023905900171

M3 - Article

VL - 14

SP - 303

EP - 310

JO - Cancer Causes and Control

JF - Cancer Causes and Control

SN - 0957-5243

IS - 4

ER -